- Home
- NTIP vs PULM Comparison
NTIP vs PULM Comparison
Compare NTIP & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- PULM
- Stock Information
- Founded
- NTIP 1990
- PULM 2003
- Country
- NTIP United States
- PULM United States
- Employees
- NTIP N/A
- PULM N/A
- Industry
- NTIP Multi-Sector Companies
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- PULM Health Care
- Exchange
- NTIP Nasdaq
- PULM Nasdaq
- Market Cap
- NTIP 28.6M
- PULM 33.2M
- IPO Year
- NTIP 1998
- PULM N/A
- Fundamental
- Price
- NTIP $1.25
- PULM $6.50
- Analyst Decision
- NTIP
- PULM
- Analyst Count
- NTIP 0
- PULM 0
- Target Price
- NTIP N/A
- PULM N/A
- AVG Volume (30 Days)
- NTIP 13.6K
- PULM 60.7K
- Earning Date
- NTIP 08-11-2025
- PULM 08-12-2025
- Dividend Yield
- NTIP 8.33%
- PULM N/A
- EPS Growth
- NTIP N/A
- PULM N/A
- EPS
- NTIP N/A
- PULM N/A
- Revenue
- NTIP $250,000.00
- PULM $1,921,000.00
- Revenue This Year
- NTIP N/A
- PULM N/A
- Revenue Next Year
- NTIP N/A
- PULM $134.88
- P/E Ratio
- NTIP N/A
- PULM N/A
- Revenue Growth
- NTIP N/A
- PULM N/A
- 52 Week Low
- NTIP $1.16
- PULM $1.78
- 52 Week High
- NTIP $1.78
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- NTIP 49.11
- PULM 39.79
- Support Level
- NTIP $1.20
- PULM $6.26
- Resistance Level
- NTIP $1.30
- PULM $6.96
- Average True Range (ATR)
- NTIP 0.05
- PULM 0.87
- MACD
- NTIP -0.00
- PULM -0.12
- Stochastic Oscillator
- NTIP 49.29
- PULM 40.16
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).